Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Around 0.3% of newborns will develop autoimmunity to pancreatic beta cells in childhood and subsequently develop type 1 diabetes before adulthood. Primary prevention of type 1 diabetes will require early intervention in genetically at-risk infants. The objective of this study was to determine to what extent genetic scores (two previous genetic scores and a merged genetic score) can improve the prediction of type 1 diabetes. METHODS AND FINDINGS: The Environmental Determinants of Diabetes in the Young (TEDDY) study followed genetically at-risk children at 3- to 6-monthly intervals from birth for the development of islet autoantibodies and type 1 diabetes. Infants were enrolled between 1 September 2004 and 28 February 2010 and monitored until 31 May 2016. The risk (positive predictive value) for developing multiple islet autoantibodies (pre-symptomatic type 1 diabetes) and type 1 diabetes was determined in 4,543 children who had no first-degree relatives with type 1 diabetes and either a heterozygous HLA DR3 and DR4-DQ8 risk genotype or a homozygous DR4-DQ8 genotype, and in 3,498 of these children in whom genetic scores were calculated from 41 single nucleotide polymorphisms. In the children with the HLA risk genotypes, risk for developing multiple islet autoantibodies was 5.8% (95% CI 5.0%-6.6%) by age 6 years, and risk for diabetes by age 10 years was 3.7% (95% CI 3.0%-4.4%). Risk for developing multiple islet autoantibodies was 11.0% (95% CI 8.7%-13.3%) in children with a merged genetic score of >14.4 (upper quartile; n = 907) compared to 4.1% (95% CI 3.3%-4.9%, P < 0.001) in children with a genetic score of ≤14.4 (n = 2,591). Risk for developing diabetes by age 10 years was 7.6% (95% CI 5.3%-9.9%) in children with a merged score of >14.4 compared with 2.7% (95% CI 1.9%-3.6%) in children with a score of ≤14.4 (P < 0.001). Of 173 children with multiple islet autoantibodies by age 6 years and 107 children with diabetes by age 10 years, 82 (sensitivity, 47.4%; 95% CI 40.1%-54.8%) and 52 (sensitivity, 48.6%, 95% CI 39.3%-60.0%), respectively, had a score >14.4. Scores were higher in European versus US children (P = 0.003). In children with a merged score of >14.4, risk for multiple islet autoantibodies was similar and consistently >10% in Europe and in the US; risk was greater in males than in females (P = 0.01). Limitations of the study include that the genetic scores were originally developed from case-control studies of clinical diabetes in individuals of mainly European decent. It is, therefore, possible that it may not be suitable to all populations. CONCLUSIONS: A type 1 diabetes genetic score identified infants without family history of type 1 diabetes who had a greater than 10% risk for pre-symptomatic type 1 diabetes, and a nearly 2-fold higher risk than children identified by high-risk HLA genotypes alone. This finding extends the possibilities for enrolling children into type 1 diabetes primary prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In those individuals who are islet autoantibody positive, HLA-DR-DQ genotyping or an analysis of Genetic Risk Score (388,392) will help define the risk of type 1 diabetes.”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [392]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A genetic risk score may be used at birth to identify children with a particularly high genetic risk of development of islet autoimmunity or type 1 diabetes (388,390,392).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [392]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“uk/) [20] and data for controls and cases from the WTCCC [21], and calculated the Winkler and Oram scores in 4,371 nondiabetic individuals who were heterozygous for HLA DR3-DQA1 0501-DQB1 0201 and DR4-DQA1 030X-DQB1 0302 (HLA DR3/DR4-DQ8) or who were homozygous for HLA DR4-DQA1 030X-DQB1 0302 (HLA DR4-DQ8/DR4-DQ8) (co…”
Kass, R. E., & Raftery, A. E. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476572 · Cited by 12,558
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Randomized trial of peanut consumption in infants at risk for peanut allergy
Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., Brough, H. A., Phippard, D., Basting, M., Feeney, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414850 · Cited by 2,237
Blanche, P., Dartigues, J., & Jacqmin‐Gadda, H. (2013) · Statistics in Medicine · doi:10.1002/sim.5958 · Cited by 1,852
The Type 1 Diabetes Genetics Consortium, Barrett, J. C., Clayton, D. G., Concannon, P., Akolkar, B., Cooper, J. D., Erlich, H. A., Julier, C., Morahan, G., Nerup, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.381 · Cited by 1,746
Self-citationSeroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Self-citationInsel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216 · cited 1×
“The presence of 2 or more islet autoantibodies (multiple islet autoantibodies) in genetically at-risk children defines a pre-symptomatic stage of type 1 diabetes where progression to type 1 diabetes is around 80% over 10 years [18,19].”
Self-citation
Cited by
Items 101–149 of 149
Bendor-Samuel, O., Wishlade, T., Willis, L., Aley, P., Choi, E., Craik, R., Mujadidi, Y., Mounce, G., Roseman, F., Gozalo, A. D. L. H., et al. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2022-324270 · Cited by 3
Self-citationZiegler, A., Ohli, J., Hoefs, T., Aydin, S., Falk, C., & Gross, J. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0337-8 · Cited by 4
Self-citationHipp, H., Tondello, C., Gmehling, H., Scholz, L. K., Stavridou, A., Becker, M., Bührer, A.-M., Hintermann, E., Dirschl, S. M., Johannsmann, T. M., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102218 · Cited by 3
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 4
Self-citationVandewalle, J., Desouter, A. K., der Auwera, B. J. R. V., Chapaza, K. B., Nobels, F. R. E., Abrams, P. J., Lebrethon, M.-C., Lapauw, B., Keymeulen, B., Gorus, F., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42156 · Cited by 3
Polygenic score from MODY genes is associated with type 1 diabetes and disease characteristics
Catamo, E., Conti, A., Franceschi, R., Dovč, K., Morosini, C., Tinti, D., Aldegheri, L., Cappellani, S., Tamaro, G., Zanfardino, A., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02544-w · Cited by 3
Imaging in Type 1 Diabetes, Current Perspectives and Directions
Tinklepaugh, J., & Mamrak, N. E. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01873-y · Cited by 4
Leeman, T., Richardson, K. P., Tran, P. M. H., & Purohit, S. B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.108248 · Cited by 2
Laboratory Guidelines Are Needed for Diagnostic Genetic Testing for Monogenic Diabetes
Hattersley, A. T. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad093 · Cited by 3
Self-citationThe willingness to participate in pediatric type 1 diabetes studies
Heinke, S., Hommel, A., Loff, A., Berner, R., & Bonifacio, E. E. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0171 · Cited by 1
Self-citationType 1 Diabetes in 2023 - From Real Practice to Open Questions
Chlup, R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100991 · Cited by 1
Actionability of Genetic Variants in Diabetes: Core Aspects and Applied Examples
Yvonnet, S., Reim, P. K., & Thuesen, A. C. B. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0081 · Cited by 1
Wright, R., Cheves, E., Wiggins, S. T., Moultrie, R., Forsythe, A., Andrews, S. M., Frawley, H. E., Cope, H., & Peay, H. L. (2026) · Journal of Community Genetics · doi:10.1007/s12687-026-00863-1 · Cited by 1
Determinants of Infant Participation and Non-Participation in Primary Prevention Trials
Wörl, F., Achenbach, P., Bonifacio, E., Casteels, K., Gemulla, G., Haupt, F., Hawkins, S., Hommel, A., King, S., Kordonouri, O., et al. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2884-2277 · Cited by 1
Self-citationPrediction of autoimmune diseases: From bench to bedside
Vivas, Á. J., & Tobón, G. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00001-3 · Cited by 1
Pediatric diabetes diagnosis: New ISPAD guidelines 2022
Zdravković, V., Ješić, M. D., Bojić, V., Kovačević, S., Blagojević, J., Miolski, J., & Didić, N. (2023) · Galenika Medical Journal · doi:10.5937/galmed2305096z · Cited by 1
Mit Big Data zu einer gezielteren Diabetes-Prävention und -Therapie
Glaser, A., & de Angelis, M. H. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00827-8 · Cited by 1
Pearce, S. H. S., & Owen, C. J. (2022) · doi:10.1093/med/9780198870197.003.0007 · Cited by 1
Aydemir, Ö., Bailey, J. A., Agardh, D., Lernmark, Å., Noble, J. A., Svärd, A. A., Blankenhorn, E. P., Parikh, H. M., Ziegler, A., Toppari, J., et al. (2023) · eLife · doi:10.7554/elife.89068 · Cited by 2
Self-citationAydemir, Ö., Bailey, J. A., Agardh, D., Lernmark, Å., Noble, J. A., Svärd, A. A., Blankenhorn, E. P., Parikh, H. M., Ziegler, A., Toppari, J., et al. (2023) · eLife · doi:10.7554/elife.89068.1 · Cited by 1
Self-citationInvestigation of glutamate receptors in human pancreatic β-cells and their role in insulin secretion
Caygill, C. H. (2020) · UWE Research Repository (UWE Bristol)
Aktuelle Entwicklungen in der Prävention des Typ-1-Diabetes
Hommel, A., & Reschke, F. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00759-3
Prediction, diagnosis, prevention and treatment: genetic-led care of patients with diabetes
Tangjittipokin, W., Borrisut, N., & Rujirawan, P. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1970526
Aktuelle Entwicklungen in der Prävention des Typ-1-Diabetes
Hommel, A., & Reschke, F. (2021) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-021-00152-x
Rajaratnam, S. M. W., Johnson‐Hart, C., Horne, B. D., & Bhatnagar, R. (2018) · British Journal of Hospital Medicine · doi:10.12968/hmed.2018.79.5.249
Aydemir, Ö., Bailey, J. A., Agardh, D., Lernmark, Å., Noble, J. A., Svärd, A. A., Blankenhorn, E. P., Parikh, H. M., Ziegler, A., Toppari, J., et al. (2026) · eLife · doi:10.7554/elife.89068.2
Self-citationMoreira, R. M., Zarife, M. M. M., Fialho, M. E. D., Nicácio, T. F., Alonso, T. D., & Pereira, A. L. C. L. (2023) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/saude/mecanismos-imunologicos
Akel, O., & Lernmark, Å. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch14 · Cited by 4
Self-citationPrevention of type 1 diabetes mellitus in children and adolescents
Bykov, Y. V. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202427011115
Alcazar, O., Chuang, S.-T., Ren, G., Ogihara, M., Webb‐Robertson, B., Nakayasu, E. S., Buchwald, P., & Abdulreda, M. H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.09.579673
Tecnología aplicada a la diabetes
Cristoforetti, M. F. (2024) · doi:10.47196/0577
Advances in type 1 diabetes: Risk factors and prevention
Amutha, A., Ranjani, H., Anjana, R. M., Unnikrishnan, R., & Mohan, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00038-3 · Cited by 1
Jinekolojik Hastalıklarda Beslenme: Güncel Yaklaşımlar
DOĞAN, H. (2024) · Bidge Yayınları eBooks · doi:10.70269/10.70269/5936429772
Jönsson, J., & Lernmark, Å. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00176-9 · Cited by 1
Self-citationXu, Z., Li, X., Yuan, X., Sun, C., Zhang, M., Chen, R., Wei, H., Chen, L., Du, H., Li, G., et al. (2025) · Pediatric Diabetes · doi:10.1155/pedi/3013063 · Cited by 1
Guertin, K. A., Repaske, D. R., Taylor, J. F., Williams, E. S., Onengut-Gumuscu, S., Chen, W.-M., Boggs, S. R., Yu, L., Allen, L., Botteon, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26680741
Self-citationClinique et diagnostic du diabète de l’enfant
Levaillant, L., Bouhours‐Nouet, N., Emeriau, F., Donzeau, A., & Coutant, R. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)50531-8
Лаптев, Д. Н., Титович, Е. В., Федоринин, А. А., Bezlepkina, O. B., Peterkova, V. A., Рамилевич, М. И., & Mokrysheva, N. G. (2026) · Diabetes Mellitus · doi:10.14341/dm13361
Clínica y diagnóstico de la diabetes en el niño
Levaillant, L., Bouhours‐Nouet, N., Emeriau, F., Donzeau, A., & Coutant, R. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)51485-5
Preimplantation genetic testing for polygenic diseases: A novel paradigm in embryo selection
Jing, T., & Du, Y. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102532 · Cited by 2
Nadal-Martínez, A., Pérez-Solero, G., López, S. F., Blom-Dahl, J., Montanya, E., Alonso-Bernáldez, M., Shabot, M., Binsch, C., Szczerbiński, Ł., Kretowski, A. J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072966
Balazard, F. (2018) · theses.fr (ABES) · doi:10.70675/b2adecfcz15c9z4ae0zb9b9z6fb540a36e2f
Onengut-Gumuscu, S., & REDONDO, M. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00014-7
Jørgensen, I. L., Damm, P., Andersen, M. K., Reim, P. K., Madsen, L. R. F., Crusell, M. K. W., Kelstrup, L., Ringholm, L., Mathiesen, E. R., Lauenborg, J., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06824-0
Fehn, A., Bonifacio, E., Bonnin, E., Casteels, K., Gündert, M., Heigermoser, M., Jönsson, I., Kordonouri, O., Loff, A., Lundgren, M., et al. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2960-5380
Self-citationPolygenic Risk Scores for Islet Autoantibody Positive Early‐Stage Type 1 Diabetes Pre‐Screening
Zapardiel‐Gonzalo, J., Winkler, C., Haupt, F., Jolink, M., Käßl, A., Hatzikotoulas, K., Ziegler, A., & Bonifacio, E. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71417
Self-citationSaso-Jiménez, L., Urrutia, I., González-Arceo, M., Diez, H., Aurrekoetxea, J., Calvo, B., Bilbao, J. R., Rica, I., Valdés, N., Huerta‐Chagoya, A., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag188
Multifaceted role of genetic and epigenetic architecture of glucose homeostasis and diabetes
Khokhar, M. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00135-z
Metadata
- Authors
- Bonifacio, E., Beyerlein, A., Hippich, M., Winkler, C., Vehik, K., Weedon, M. N., Laimighofer, M., Hattersley, A. T., Krumsiek, J., Frohnert, B. I., Steck, A. K., Hagopian, W. A., Krischer, J. P., Lernmark, Å., Rewers, M. J., She, J.-X., Toppari, J., Akolkar, B., Oram, R. A., Rich, S. S., Ziegler, A.-G., & for the TEDDY Study Group
- Affiliations
- Center for Regenerative Therapies Dresden (DE)
- TUM Klinikum (DE)
- University of South Florida (US)
- University of Exeter (GB)
- Helmholtz Munich (DE)
- University of Colorado Denver (US)
- Pacific Northwest Research Institute (US)
- Lund University (SE)
- Augusta University (US)
- University of Turku (FI)
- National Institutes of Health (US)
- University of Alberta (CA)
- University of Virginia (US)
- Corresponding author
- Ziegler, Anette-G.
- ORCID
- Bonifacio, Ezio
- Beyerlein, Andreas
- Hippich, Markus
- Winkler, Christiane
- Vehik, Kendra
- Weedon, Michael N.
- Laimighofer, Michael
- Hattersley, Andrew T.
- Krumsiek, Jan
- Frohnert, Brigitte I.
- Steck, Andrea K.
- Hagopian, William A.
- Krischer, Jeffrey P.
- Lernmark, Åke
- Rewers, Marian J.
- She, Jin-Xiong
- Toppari, Jorma
- Akolkar, Beena
- Oram, Richard A.
- Rich, Stephen S.
- Ziegler, Anette-G.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-04-03
- Volume
- 15
- Issue
- 4
- Pages
- e1002548
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5882115
- OpenAlex
- W2795575996
- Cited by
- 148
- References
- 36
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 19 · 2023: 19 · 2022: 23 · 2021: 12 · 2020: 16 · 2019: 15 · 2018: 11
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- UTUPub (University of Turku) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Site cant be reached (submittedVersion, cc-by)
- Open Research Exeter (University of Exeter) (submittedVersion, public-domain)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, public-domain)
- Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, and Contract No. HHSN267200700014C)
- National Institute of Allergy and Infectious Diseases
- National Institute of Child Health and Human Development
- National Institute of Environmental Health Sciences
- Juvenile Diabetes Research Foundation International
- Centers for Disease Control and Prevention
- NIH/NCATS Clinical and Translational Science Awards (UL1 TR000064)
- University of Colorado (UL1 TR001082)
- iMed–the Helmholtz Initiative on Personalized Medicine
- DFG Research Center and Cluster of Excellence - Center for Regenerative Therapies Dresden (FZ 111)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 1 diabetes, islet autoantibodies, polygenic risk score, risk prediction, single nucleotide polymorphisms, TEDDY study, primary prevention, islet autoimmunity, risk stratification
- MeSH terms
- Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Genetic Testing, Humans, Infant, Infant, Newborn, Islets of Langerhans, Male, Risk Factors, Case-Control Studies, Risk Assessment, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.